Search companies

Live

Tuesday, 17 November 2026 · 583 Summaries Today

S&P/ASX 200 · 8,883.20 (-1.79%)

Ceryvyn Advances LAM Drug Program, Cash Falls To $28 Million

CYV: $0.010 +0.00% · MC: $12M

Ceryvyn Therapeutics says preclinical and inhalation studies for its LAM drug candidate remain on track, and it has contracted to use Xe-MRI in a planned early signal-finding study; an advisory board supported the approach, subject to Stage 1 preclinical requirements. Cash and equivalents fell to approximately $28 million from $30 million at the prior quarter-end, while quarterly operating cash outflow increased from the previous quarter. The company has selected a contract research organisation for the next development stage, with study scope and agreements still to be finalised.

Source announcements: 2026-10-29 09:27 to 2026-10-29 09:27 Sydney time
Story updated 2026-10-29 09:37 Sydney time
SourcesQuarterly Activities/Appendix 4C Cash Flow Report
Comments